Collaboration to advance manufacturing of regenerative medicine and biotherapeutics
A collaboration between Mayo Clinic and National Resilience Inc. hopes to advance the biomanufacturing and delivery of novel biologic therapeutics for rare and complex conditions.
Mayo Clinic have announced a strategic collaboration with National Resilience Inc. in Rochester, Minnesota for the biomanufacturing of novel biotherapeutics for rare and complex conditions, centring Rochester as a hub for regenerative medicine manufacturing.
The collaboration hopes to focus on biologic therapies by bringing together innovative science and engineering for the manufacturing of therapies utilizing cells, blood, enzymes, tissues, genes, and genetically engineered cells. Biologics encompass any range of therapeutics that are isolated from biological sources, whether all or partially synthesized. Such therapies include vaccines, blood and blood components, allergenics, cell and gene therapies, and recombinant therapeutic proteins. Julie Allickson, Director of Mayo Clinic’s Center for Regenerative Medicine, commented: “This nexus of entrepreneurs, start-ups, and industry experts will help position Mayo Clinic as an authority in regenerative biotherapeutics.”
National Resilience and Mayo Clinic hope to collaborate and focus on the advancement of Mayo Clinic biotherapeutics with expertise in process development, the attraction of biotech companies for clinical trial sponsorship, providing cell and gene therapy products required for early-stage therapeutics biomanufacturing and analytical testing and quality control for manufacturing commercial-grade biopharmaceuticals. All areas of focus are committed to the advancement of biomanufacturing in new biologic-based medicines in hopes of accelerating clinical care options for patients of rare and complex conditions, which the collaboration hopes to provide.
Kinney Executive Dean of Research at Mayo Clinic Gregory Gores stated: “Mayo Clinic will advance regenerative technologies from discovery science to early phase clinical trials… Research in the emerging field of biotherapeutics lays the foundation to attract the scientific workforce of the future.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance